General Information of Drug (ID: DM9PQ2N)

Drug Name
RO-23-7553 Drug Info
Synonyms
BXL-353; ILX-23-7553; (1alpha,3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19),16-tetraen-23-yne-1,3,25-triol; 1alpha,25-Dihydroxy-16,17,23,23,24,24-hexadehydrocholecalciferol; 1alpha,25-Dihydroxy-16,17,23,23,24,24-hexadehydrovitamin D3
Indication
Disease Entry ICD 11 Status REF
Prostate disease GA91 Phase 1 [1]
Cross-matching ID
PubChem CID
6438384
CAS Number
CAS 118694-43-2
TTD Drug ID
DM9PQ2N

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Vitamin D3 receptor (VDR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ergocalciferol DMHO0AR Hypoparathyroidism 5A50 Approved [3]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [4]
Calcidiol DMN4CV5 Hypophosphatemia Approved [3]
Doxercalciferol DM6FG1P Chronic kidney disease GB61 Approved [5]
Calcipotriol DM03CP7 Psoriasis EA90 Approved [6]
Falecalcitrol DMBI9ZJ Hyperparathyroidism 5A51 Approved [7]
Dihydrotachysterol DMFB97P Hypocalcemia 5B5K.1 Approved [8]
Cholecalciferol DMGU74E Adult acute monocytic leukemia Approved [9]
Paricalcitol DMYBV3G Hyperparathyroidism 5A51 Approved [10]
Seocalcitol DMKL9QO Rickets 5B57 Phase 3 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Vitamin D3 receptor (VDR) TTK59TV VDR_HUMAN Agonist [2]

References

1 ClinicalTrials.gov (NCT00004926) ILX23-7553 in Treating Patients With Solid Tumors That Have Not Responded to Previous Therapy. U.S. National Institutes of Health.
2 Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion. Clin Cancer Res. 1997 Aug;3(8):1331-8.
3 Vitamin D in health and disease. Clin J Am Soc Nephrol. 2008 Sep;3(5):1535-41.
4 Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist. Blood. 2000 Nov 1;96(9):3188-94.
5 Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
6 Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets. 2008 Apr;9(4):345-59.
7 Synthesis and biological evaluations of A-ring isomers of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3. Bioorg Med Chem. 2000 Aug;8(8):2157-66.
8 In vivo metabolism of the vitamin D analog, dihydrotachysterol. Evidence for formation of 1 alpha,25- and 1 beta,25-dihydroxy-dihydrotachysterol metabolites and studies of their biological activity. J Biol Chem. 1993 Jan 5;268(1):282-92.
9 [Vitamin D2 or vitamin D3]. Rev Med Interne. 2008 Oct;29(10):815-20.
10 New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor... Contrib Nephrol. 2009;163:219-226.
11 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.